Geneoscopy, a ST Louis, MO-based life sciences company focused on development of diagnostic tests for gastrointestinal health, raised $105M in Series B funding.
The round was led by Lightchain Capital and NT Investments with participation from Morningside Ventures, Labcorp, Cultivation Capital, BioGenerator Ventures and Innovatus Capital Partners.
The company intends to use the funds to support the U.S. CRC-PREVENT pivotal trial, scale commercial infrastructure, and expand its diagnostic product pipeline.
Led by Andrew Barnell, CEO, Geneoscopy is a life sciences company focused on the development of diagnostic tests for gastrointestinal health. Its lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded Breakthrough Device Designation from the US FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Preliminary trials suggest that the diagnostic can detect these lesions at a higher rate than all existing noninvasive screening tests.